Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.
Limited data are available on the kinetics of meningococcal serogroup C (MenC)-specific antibody responses following parenteral or nasal challenge in those who have received prior MenC vaccination (polysaccharide or conjugate). Young adults who had previously received either meningococcal A/C polysaccharide (MACP) or MenC conjugate (MCC) vaccine or naïve subjects were challenged with MACP via one of two routes, nasal or parenteral. Blood samples were taken prevaccination and on days 1 to 4 and day 10 postvaccination. MenC serum bactericidal antibody (SBA) and MenC-specific IgG were measured. Following parenteral challenge, MenC SBA and IgG responses were seen to occur between 4 and 7 days postchallenge. A lower proportion of subjects responded following nasal challenge, with naïve subjects showing little change in SBA geometric mean titer (GMT) and IgG geometric mean concentration (GMC) over the 10 days following challenge. Increases in SBA GMTs were seen between 4 and 7 days after nasal challenge in those who had received prior MCC and between 7 and 10 days in those who had received prior MACP, and the responses in the prior-MACP group were of lower magnitude than the responses of the prior-MCC group. The data presented here indicate that, following MCC vaccination, memory has been induced at the mucosal level, and these subjects were able to respond with increases in SBA levels. These results demonstrate that the speed of response (primary or secondary) to challenge with MenC polysaccharide via the nasal or parenteral route does not differ and support concerns that immunological memory alone is too slow to provide protection.
Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom. Helen.findlow@hpa.org.uk
H
H
Findlow
R
R
Borrow
P
P
Hardelid
E
E
Newton
S
S
Frankland
S
S
Naylor
E
E
Miller
E
E
Kaczmarski
R C
RC
Read
D000281:Administration, Intranasal; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D001770:Blood Bactericidal Activity; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007156:Immunologic Memory; D007275:Injections, Intravenous; D008297:Male; D022401:Meningococcal Vaccines / Q000276:immunology*; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D013997:Time Factors
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial
Infect Immun. 2001 Jul;69(7):4337-41
11401971
J Infect Dis. 2001 Jan 1;183(1):160-3
11078484
J Infect Dis. 1999 Jun;179(6):1569-72
10228085
J Infect Dis. 2006 Dec 15;194(12):1745-52
17109348
J Infect Dis. 1994 Apr;169(4):847-52
8133100
Vaccine. 2001 Oct 15;20 Suppl 1:S58-67
11587814
Vaccine. 2001 Apr 30;19(23-24):3043-50
11311998
Vaccine. 2000 Jun 1;18(24):2686-92
10781855
Vaccine. 2009 Nov 23;27(50):6974-82
19800445
J Clin Microbiol. 1992 Jan;30(1):154-9
1734048
Clin Diagn Lab Immunol. 1995 Mar;2(2):132-7
7697519
J Exp Med. 1969 Jun 1;129(6):1327-48
4977281
Pediatr Infect Dis J. 2002 Mar;21(3):209-13
12005084
Vaccine. 2000 Oct 15;19(4-5):547-56
11027820
Lancet. 2002 May 25;359(9320):1829-31
12044380
Pediatr Infect Dis J. 1995 Apr;14(4):286-94
7603810
Infect Immun. 2000 May;68(5):2692-7
10768961
BMJ. 2003 Feb 15;326(7385):365-6
12586669
Clin Vaccine Immunol. 2006 Aug;13(8):854-61
16893984
Clin Infect Dis. 2006 Dec 1;43(11):1387-94
17083009
J Infect Dis. 2002 Nov 1;186(9):1353-7
12402208
Clin Diagn Lab Immunol. 2003 Sep;10(5):780-6
12965904
Nat Rev Immunol. 2009 Mar;9(3):213-20
19214194
J Infect Dis. 2008 Mar 1;197(5):737-43
18271745
Clin Diagn Lab Immunol. 1997 Mar;4(2):156-67
9067649